Port site resection after laparoscopy in advance ovarian cancer surgery: Time to abandon?


Journal

Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 20 06 2018
revised: 30 11 2018
accepted: 27 01 2019
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 19 12 2019
Statut: ppublish

Résumé

The use of laparoscopy in the treatment and management of advanced ovarian cancer is increasing among the gynaecologic oncologists. The development of port site metastases after laparoscopy is a concern and a matter of debate due to theoretical iatrogenic disease spread. Port site resection (PSR) has been proposed as an option to avoid this scenario. One hundred and twenty-three patients with advanced ovarian cancer (FIGO III-IV) and with diagnostic laparoscopy were included and after cytoreductive surgery were classified into two groups: no port site resection (No-PSR) and port site resection (PSR). Based on the pathological results of all port site specimens, PSR was classified as positive port site metastasis (PSM+) and negative port site metastasis (PSM-). In 82 cases, the laparoscopic port site access was resected in the debulking surgery. At the final specimen examination, 49% presented as PSM+. No statistical differences regarding survival were found, either between the No-PSR and PSR groups (p = 0.28) or between the PSM+ and PSM - groups (p = 0.92). A higher wound complication rate was found in the PSR group (17% vs. 34%; p = 0.047). The RR (Relative Risk) of wound events for PSR was 2.42 (95% CI 1.09-5.35; p = 0.0296). To date, not only there is no data supporting PSR after laparoscopy in advanced ovarian cancer, but the role of PSM+ in prognosis also remains unclear. In patients in which laparoscopy is performed prior to the debulking procedure, the PSR may not be recommended in those cases of no macroscopic port site metastasis.

Identifiants

pubmed: 31196470
pii: S0960-7404(18)30249-4
doi: 10.1016/j.suronc.2019.01.007
pii:
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-6

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Víctor Lago (V)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain. Electronic address: victor.lago.leal@hotmail.com.

Laura Gimenez (L)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

Luis Matute (L)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

Pablo Padilla-Iserte (P)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

José Miguel Cárdenas-Rebollo (JM)

Department of Applied Mathematics and Statistics CEU San Pablo University, Madrid, Spain.

Marta Gurrea (M)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

Beatriz Montero (B)

Department of Pathology, University Hospital La Fe, Valencia, Spain.

Guillermina Montoliu (G)

Department of Radiology, University Hospital La Fe, Valencia, Spain.

Santiago Domingo (S)

Department of Gynecologic Oncology, University Hospital La Fe, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH